[{"address1": "5858 Horton Street", "address2": "Suite 455", "city": "EmeryVille", "state": "CA", "zip": "94608", "country": "United States", "phone": "510 505 2680", "website": "https://www.4dmoleculartherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. Its lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. The company is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in in preclinical stage for treating geographic atrophy; 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease; and 4D-310 that is in Phase 1 clinical trial for treating Fabry disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Astellas Gene Therapies, Inc.; Arbor Biotechnologies, Inc.; and uniQure biopharma B.V. The company was founded in 2013 and is headquartered in Emeryville, California.", "fullTimeEmployees": 227, "companyOfficers": [{"maxAge": 1, "name": "Dr. John F. Milligan Ph.D.", "age": 63, "title": "Executive Chairman", "yearBorn": 1961, "fiscalYear": 2024, "totalPay": 150000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David H. Kirn M.D.", "age": 62, "title": "Co-Founder, CEO & Director", "yearBorn": 1962, "fiscalYear": 2024, "totalPay": 1009003, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Fariborz  Kamal Ph.D.", "age": 61, "title": "President & COO", "yearBorn": 1963, "fiscalYear": 2024, "totalPay": 734607, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Theresa  Janke", "age": 49, "title": "Co-Founder & Chief of Staff", "yearBorn": 1975, "fiscalYear": 2024, "totalPay": 652315, "exercisedValue": 0, "unexercisedValue": 703125}, {"maxAge": 1, "name": "Dr. Scott P. Bizily J.D., Ph.D.", "age": 52, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1972, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. An  Song Ph.D.", "title": "Chief Translational Medicine Advisor", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 6, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1756684800, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 7.1, "open": 6.96, "dayLow": 6.6, "dayHigh": 7.15, "regularMarketPreviousClose": 7.1, "regularMarketOpen": 6.96, "regularMarketDayLow": 6.6, "regularMarketDayHigh": 7.15, "payoutRatio": 0.0, "beta": 2.848, "forwardPE": -2.006079, "volume": 1103599, "regularMarketVolume": 1103599, "averageVolume": 1136315, "averageVolume10days": 576050, "averageDailyVolume10Day": 576050, "bid": 6.58, "ask": 6.66, "bidSize": 1, "askSize": 1, "marketCap": 308236288, "fiftyTwoWeekLow": 2.235, "fiftyTwoWeekHigh": 11.765, "priceToSalesTrailing12Months": 9340.493, "fiftyDayAverage": 5.9112, "twoHundredDayAverage": 4.806325, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 38088284, "profitMargins": 0.0, "floatShares": 35704503, "sharesOutstanding": 46702467, "sharesShort": 4295623, "sharesShortPriorMonth": 3703248, "sharesShortPreviousMonthDate": 1753920000, "dateShortInterest": 1756425600, "sharesPercentSharesOut": 0.092, "heldPercentInsiders": 0.03849, "heldPercentInstitutions": 0.86941004, "shortRatio": 1.9, "shortPercentOfFloat": 0.095699996, "impliedSharesOutstanding": 50240533, "bookValue": 9.013, "priceToBook": 0.7322756, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -196144000, "trailingEps": -3.53, "forwardEps": -3.29, "enterpriseToRevenue": 1154.19, "enterpriseToEbitda": -0.176, "52WeekChange": -0.43152457, "SandP52WeekChange": 0.1653893, "quoteType": "EQUITY", "currentPrice": 6.6, "targetHighPrice": 45.0, "targetLowPrice": 10.0, "targetMeanPrice": 30.4, "targetMedianPrice": 33.0, "recommendationMean": 1.91667, "recommendationKey": "buy", "numberOfAnalystOpinions": 10, "totalCash": 293224992, "totalCashPerShare": 6.279, "ebitda": -215823008, "totalDebt": 23077000, "quickRatio": 8.456, "currentRatio": 8.746, "totalRevenue": 33000, "debtToEquity": 5.483, "revenuePerShare": 0.001, "returnOnAssets": -0.2518, "returnOnEquity": -0.38869998, "grossProfits": -170188992, "freeCashflow": -94590752, "operatingCashflow": -166388992, "revenueGrowth": 2.0, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -3963.7334, "financialCurrency": "USD", "symbol": "FDMT", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "longName": "4D Molecular Therapeutics, Inc.", "corporateActions": [], "exchange": "NMS", "messageBoardId": "finmb_272879653", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "shortName": "4D Molecular Therapeutics, Inc.", "regularMarketChangePercent": -7.04225, "regularMarketPrice": 6.6, "marketState": "CLOSED", "postMarketTime": 1758321636, "regularMarketTime": 1758312003, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1607697000000, "postMarketChangePercent": 1.9697, "postMarketPrice": 6.73, "postMarketChange": 0.13, "regularMarketChange": -0.5, "regularMarketDayRange": "6.6 - 7.15", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1136315, "fiftyTwoWeekLowChange": 4.365, "fiftyTwoWeekLowChangePercent": 1.9530201, "fiftyTwoWeekRange": "2.235 - 11.765", "fiftyTwoWeekHighChange": -5.1650004, "fiftyTwoWeekHighChangePercent": -0.43901405, "fiftyTwoWeekChangePercent": -43.15246, "earningsTimestamp": 1754915400, "earningsTimestampStart": 1762777800, "earningsTimestampEnd": 1762777800, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -3.53, "epsForward": -3.29, "epsCurrentYear": -3.6937, "priceEpsCurrentYear": -1.7868261, "fiftyDayAverageChange": 0.68879986, "fiftyDayAverageChangePercent": 0.11652454, "twoHundredDayAverageChange": 1.793675, "twoHundredDayAverageChangePercent": 0.37319052, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2020-12-11", "averageAnalystRating": "1.9 - Buy", "cryptoTradeable": false, "displayName": "4D Molecular Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-09-20"}]